공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 치료 및 예방 백신 시장(2019-2025년)

Global Therapeutic and Preventive Vaccine Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2019년 12월 상품 코드 920444
페이지 정보 영문
가격
US $ 3,600 ₩ 3,998,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,330,000 Printable PDF (Enterprise License)


세계의 치료 및 예방 백신 시장(2019-2025년) Global Therapeutic and Preventive Vaccine Market 2019-2025
발행일 : 2019년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 치료 및 예방 백신 시장은 예측기간 중 9.3%라는 놀라운 성장률로 확대될 것으로 예측됩니다. 시장 성장을 촉진하는 주요 요인으로 세계적인 암 및 기타 감염 등 만성 질환 유병률의 증가를 들 수 있습니다. 정부 지출은 암의 치료를 위해 현저하게 증가하고 있습니다. 미국에서 2010년 암 치료에 대한 국가 지출은 1,250억 달러에 근접했으며, 2020년에는 1,560억 달러에 달할 것으로 예상됩니다. 유방암은 여성 사망률의 주요 원인 중 하나입니다. 미국에서는 2017년에 252,000개 이상의 유방암에 대한 새로운 사례가 있었습니다. 이러한 수치는 백신 접종의 필요성을 반영하고, 그 결과 시장 성장이 촉진됩니다. 또한 DNA 백신 등 혁신적인 백신의 개발에 대한 관심 고조와 중국과 인도 등 신흥 경제 국가에서 백신 접종의 혜택에 대한 의식 고조가 시장 성장을 더욱 강화하고 있습니다.

세계의 치료 및 예방 백신(Therapeutic and Preventive Vaccine) 시장에 대해 조사 분석했으며, 시장 개요, 시장 결정요인, 시장 세분화, 경쟁 상황, 지역별 분석, 주요 기업 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 보고서 개요

  • 조사 방법과 수단
  • 시장 분석
    • 부문별
    • 지역별

제2장 시장 개요와 인사이트

  • 보고서의 범위
  • 애널리스트의 견해와 최신 시장 동향
    • 주요 조사 결과
    • 제안
    • 결론
  • 규칙 및 규제

제3장 경쟁 상황

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Sanofi SA
    • Pfizer Inc.
    • GlaxoSmithKline PLC
    • Merck & Co.
    • AstraZeneca PLC

제4장 시장 결정요인

  • 성장 촉진요인
  • 성장 저해요인
  • 시장 기회

제5장 시장 세분화

  • 종류별 시장
    • 치료 백신
    • 예방 백신
  • 질병 종류별 시장
    • 자가 면역 질환
    • 신경 질환
    • 감염
  • 백신 종류별 치료 백신 시장
    • 동종 백신
    • 자가 백신
  • 질병 종류별 예방 백신 시장
    • 폐렴구균
    • 폴리오바이러스
    • 간염
    • 인플루엔자
    • 홍역, 유행성 이하선염 및 풍진
    • 기타(수두)
  • 백신 종류별 예방 백신 시장
    • 생백신/약독 백신
    • 불활화 백신
    • 결합 백신
    • DNA 백신
    • 기타(재조합 벡터 백신)
  • 최종사용자별 시장
    • 인간
    • 동물

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 기타
  • 기타 지역

제7장 기업 개요

  • Agenus Inc.
  • Argos Therapeutic Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Celldex Therapeutic Inc.
  • CSL Ltd.
  • Cytos Biotechnology AG
  • Daiichi Sankyo Co. Ltd
  • Dendreon Corp
  • Emergent BioSolutions Inc.
  • GC Pharma(Green Cross Corp.)
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co.
  • Novartis International AG
  • Novavax Inc.
  • Pfizer Inc.
  • Qed Biosciences Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Vaccinogen Inc.
  • Xenetic Biosciences, Inc.
  • Zoetis Inc.
KSM 20.01.30

List of Tables

  • 1. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL NEUROLOGICAL DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL CANCER THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL INFECTIOUS DISEASE THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2018-2025 ($ MILLION)
  • 10. GLOBAL ALLOGENEIC THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 11. GLOBAL AUTOLOGOUS THERAPEUTIC VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 12. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 13. GLOBAL PREVENTIVE VACCINE FOR PNEUMOCOCCAL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 14. GLOBAL PREVENTIVE VACCINE FOR POLIOVIRUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 15. GLOBAL PREVENTIVE VACCINE FOR HEPATITIS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 16. GLOBAL PREVENTIVE VACCINE FOR INFLUENZA DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 17. GLOBAL PREVENTIVE VACCINE FOR MMR DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 18. GLOBAL PREVENTIVE VACCINE FOR OTHER DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 19. GLOBAL PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2018-2025 ($ MILLION)
  • 20. GLOBAL LIVE/ATTENUATED PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 21. GLOBAL INACTIVATED PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 22. GLOBAL CONJUGATE PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 23. GLOBAL DNA PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 24. GLOBAL OTHER PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 25. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 26. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE FOR HUMAN MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 27. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE FOR ANIMAL MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 28. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 29. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 30. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 31. NORTH AMERICAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 32. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 33. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 34. EUROPEAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 35. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 36. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 37. ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 38. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
  • 39. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

List of Figures

  • 1. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY END-USER, 2018 VS 2025 (%)
  • 3. GLOBAL THERAPEUTIC AND PREVENTIVE VACCINE MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. INDIA THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD THERAPEUTIC AND PREVENTIVE VACCINE MARKET SIZE, 2018-2025 ($ MILLION)

The global therapeutic and preventive vaccine market is estimated to grow at an impressive growth rate of 9.3% during the forecast period. Major factors that augment the market growth include the rising prevalence of chronic diseases such as cancer and other infectious diseases across the globe. The expenditure of the government is increasing significantly for the cure for cancer. In the US, national expenditures for cancer care were near to $125 billion in 2010 and it is expected to reach $156 billion in 2020. Breast cancer is one of the leading causes of mortality among women. In the US, there were more than 252,000 new cases of breast cancer in 2017. These figures reflect the need for vaccination; thereby, augmenting the market growth. Moreover, growing focus on the development of innovative vaccines such as DNA vaccines and growing awareness towards the benefits of vaccination in emerging economies such as China and India is further augmenting the market growth.

The global therapeutic and preventive vaccine market is segmented on the basis of type, end-user, and region. On the basis of type, the market is broadly classified into the therapeutic vaccine and preventive vaccine. The global therapeutic vaccine market is analyzed on the basis of disease type and vaccine type. On the basis of disease, the therapeutic vaccine market is sub-segmented into autoimmune disease vaccine, neurological disease vaccine, and cancer vaccine. On the basis of vaccine type, the market is analyzed into an allogeneic vaccine and autologous vaccine. Whereas, the global preventive vaccine market is further segmented on the basis of vaccine type and disease type. On the basis of vaccine type, the market is classified into live/attenuated vaccine, inactivated vaccine, conjugate vaccine, DNA vaccines, and others. Based on disease type, the market analyzes pneumococcal, poliovirus, hepatitis, influenza, measles, mumps, and rubella and others. Based on the end-user, the global therapeutic and preventive vaccine market is divided into human vaccines and animal vaccines.

Geographically, the market is analyzed into North America, Europe, Asia-Pacific, and the Rest of the World. North America held the dominating position in the global therapeutic and preventive vaccine market in 2018 and is further estimated to follow the same trend over the forecast period. The major factors contributing to the growth of the North American market include the presence of well-developed healthcare infrastructure, the number of researches carried out on vaccination and fund provided to the companies and institutions, unhealthy lifestyle and growing focus on the treatment of cancer. Further, Asia-Pacific is estimated to be the fastest-growing region during the forecast period. Moreover, the global therapeutic and preventive vaccine market is influenced by the presence of several players including Sanofi SA, Pfizer Inc., GlaxoSmithKline PLC, Merck & Co., AstraZeneca PLC, and many others. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the global therapeutic and preventive vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Authenticate databases such as the World Health Organizations (WHO), the National Institute of Health (NIH), and others.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for therapeutic and preventive vaccine manufacturers, research organizations, pharmaceutical drug manufacturing companies, biotechnology companies, venture capitalists, market research firms, government organizations and regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Therapeutic and Preventive Vaccine Market Research and Analysis by Type

2. Global Therapeutic and Preventive Vaccine Market Research and Analysis by End-User

The Report covers:

  • Comprehensive research methodology of the global therapeutic and preventive vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global therapeutic and preventive vaccine market.
  • Insights about market determinants which are stimulating the global therapeutic and preventive vaccine market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Sanofi SA
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. GlaxoSmithKline PLC
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Merck & Co.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. AstraZeneca PLC
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Therapeutic and Preventive Vaccine Market by Type
    • 5.1.1. Therapeutic Vaccine
    • 5.1.2. Preventive Vaccine
  • 5.2. Global Therapeutic Vaccine Market by Disease Type
    • 5.2.1. Autoimmune Disease
    • 5.2.2. Neurological Disease
    • 5.2.3. Cancer
    • 5.2.4. Infectious Disease
  • 5.3. Global Therapeutic Vaccine Market by Vaccine Type
    • 5.3.1. Allogeneic Vaccine
    • 5.3.2. Autologous Vaccine
  • 5.4. Global Preventive Vaccine Market by Disease Type
    • 5.4.1. Pneumococcal
    • 5.4.2. Poliovirus
    • 5.4.3. Hepatitis
    • 5.4.4. Influenza
    • 5.4.5. Measles, Mumps, and Rubella
    • 5.4.6. Others (Varicella)
  • 5.5. Global Preventive Vaccine Market by Vaccine Type
    • 5.5.1. Live/Attenuated Vaccine
    • 5.5.2. Inactivated Vaccine
    • 5.5.3. Conjugate Vaccine
    • 5.5.4. DNA Vaccines
    • 5.5.5. Others (Recombinant Vector Vaccines)
  • 5.6. Global Therapeutic and Preventive Vaccine Market by End-User
    • 5.6.1. Human
    • 5.6.2. Animal

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. Japan
    • 6.3.3. India
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Agenus Inc.
  • 7.2. Argos Therapeutic Inc.
  • 7.3. Astellas Pharma Inc.
  • 7.4. AstraZeneca PLC
  • 7.5. Celldex Therapeutic Inc.
  • 7.6. CSL Ltd.
  • 7.7. Cytos Biotechnology AG
  • 7.8. Daiichi Sankyo Co. Ltd
  • 7.9. Dendreon Corp
  • 7.10. Emergent BioSolutions Inc.
  • 7.11. GC Pharma (Green Cross Corp.)
  • 7.12. GlaxoSmithKline PLC
  • 7.13. Johnson & Johnson Services Inc.
  • 7.14. Merck & Co.
  • 7.15. Novartis International AG
  • 7.16. Novavax Inc.
  • 7.17. Pfizer Inc.
  • 7.18. Qed Biosciences Inc.
  • 7.19. Sanofi SA
  • 7.20. Takeda Pharmaceutical Co. Ltd.
  • 7.21. Vaccinogen Inc.
  • 7.22. Xenetic Biosciences, Inc.
  • 7.23. Zoetis Inc.
Back to Top
전화 문의
F A Q